Literature DB >> 20038967

Prevalence of chronic renal disease in Spain: results of the EPIRCE study.

Alfonso Otero1, Angel de Francisco, Pilar Gayoso, Fernando García.   

Abstract

INTRODUCTION: Chronic kidney disease (CKD) is an independent cardiovascular risk factor. The knowledge of prevalence in general population may help to early detection of CKD and prevent or delay its progression.
METHODS: Sociodemographic, baseline characteristics, and CKD prevalence (measured by centralized serum creatinine and MDRD equation) were evaluated in a randomly selected sample of general population aged 20 years or older, collected in all Spanish regions and stratified by habitat, age and sex according to 2001 census (n=2746). Univariate and multivariate logistic regression analyses were used to evaluate associations with CKD risk factors.
RESULTS: Mean age was 49.5 years. The overall prevalence of Kidney Disease Outcomes Quality Initiative grades 3-5 CKD was 6.8%, with a 95% confidence interval (CI) of 5.4 to 8.2 (3.3% for age 40-64 years and 21.4% for age > 64 years). The prevalence estimates of CKD stages were: 0.99% for stage 1 (glomerular filtration rate [GFR] >or=90 ml/min per 1.73 m2 with proteinuria); 1.3% for stage 2 (GFR 60-89); 5.4% for stage 3a (GFR 45-59); 1.1% for stage 3b (GFR 30-44); 0.27% for stage 4 (GFR 15-29); and 0.03% for stage 5 (GFR < 15). An important prevalence of classical cardiovascular risk factors was observed: dyslipemia (29.3%), obesity (26.1%), hypertension (24.1%), diabetes (9.2%) and current smoking (25.5%). The independent predictor factors for CKD were age, obesity and previously diagnosed hypertension.
CONCLUSION: The prevalence of CKD at any stage in general population from Spain is relatively high, especially in the elderly, and similar to countries of the same geographical area. Independently of age, two modifiable risks factors, hypertension and obesity, are associated with an increased prevalence of CKD.

Entities:  

Mesh:

Year:  2009        PMID: 20038967     DOI: 10.3265/Nefrologia.pre2009.Dic.5732

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  51 in total

1.  Motivational interviewing promotes adherence and improves wellbeing in pre-dialysis patients with advanced chronic kidney disease.

Authors:  Helena García-Llana; Eduardo Remor; Gloria del Peso; Olga Celadilla; Rafael Selgas
Journal:  J Clin Psychol Med Settings       Date:  2014-03

2.  Effectiveness of pharmacist intervention in patients with chronic kidney disease.

Authors:  Aurelio Cabello-Muriel; Juan José Gascón-Cánovas; Elena Urbieta-Sanz; Carles Iniesta-Navalón
Journal:  Int J Clin Pharm       Date:  2014-08-20

3.  Chronic dietary exposure to aristolochic acid and kidney function in native farmers from a Croatian endemic area and Bosnian immigrants.

Authors:  Bojan Jelaković; Ivana Vuković Lela; Sandra Karanović; Živka Dika; Jelena Kos; Kathleen Dickman; Maja Šekoranja; Tamara Poljičanin; Maja Mišić; Vedran Premužić; Mirta Abramović; Vesna Matijević; Marica Miletić Medved; Ante Cvitković; Karen Edwards; Mirjana Fuček; Ninoslav Leko; Tomislav Teskera; Mario Laganović; Dubravka Čvorišćec; Arthur P Grollman
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-13       Impact factor: 8.237

4.  Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis.

Authors:  Gonzalo Gutiérrez-García; Jesús Villarreal; Marta Garrote; Montserrat Rovira; Miquel Blasco; María Suárez-Lledó; Luis Gerardo Rodríguez-Lobato; Paola Charry; Laura Rosiñol; Pedro Marín; Alexandra Pedraza; María Teresa Solano; Carla Ramos; Noemí de Llobet; Miquel Lozano; Joan Cid; Carmen Martínez; Esteban Poch; Enric Carreras; Álvaro Urbano-Ispizua; Francesc Fernández-Avilés; A Pereira; Luis F Quintana
Journal:  Bone Marrow Transplant       Date:  2020-02-26       Impact factor: 5.483

Review 5.  Dialysis-treated end-stage kidney disease in Libya: epidemiology and risk factors.

Authors:  Fathea Abobker Goleg; Norella Chiew-Tong Kong; Ramesh Sahathevan
Journal:  Int Urol Nephrol       Date:  2014-03-27       Impact factor: 2.370

Review 6.  Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease.

Authors:  Juan Jesus Carrero; Manfred Hecking; Nicholas C Chesnaye; Kitty J Jager
Journal:  Nat Rev Nephrol       Date:  2018-01-22       Impact factor: 28.314

7.  Prescribing patterns of non-steroidal anti-inflammatory drugs in chronic kidney disease patients in the South African private sector.

Authors:  Willem P Meuwesen; Jesslee M du Plessis; Johanita R Burger; Martie S Lubbe; Marike Cockeran
Journal:  Int J Clin Pharm       Date:  2016-04-18

8.  The H.U.G.E. Formula (Hematocrit, Urea, Sex) for Screening Chronic Kidney Disease (CKD) in an Age-Stratified General Population.

Authors:  N R Robles; F J Felix; L Lozano; I Miranda; D Fernandez-Berges; J F Macías
Journal:  J Nutr Health Aging       Date:  2015-06       Impact factor: 4.075

9.  Budget Impact Analysis of Oral Fisiogen Ferro Forte® versus Intravenous Iron for the Management of Iron Deficiency in Chronic Kidney Disease in Spain.

Authors:  Josep Darbà; Meritxell Ascanio
Journal:  Clin Drug Investig       Date:  2018-09       Impact factor: 2.859

10.  Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.

Authors:  Giuseppe Boriani; Irina Savelieva; Gheorghe-Andrei Dan; Jean Claude Deharo; Charles Ferro; Carsten W Israel; Deirdre A Lane; Gaetano La Manna; Joseph Morton; Angel Moya Mitjans; Marc A Vos; Mintu P Turakhia; Gregory Y H Lip
Journal:  Europace       Date:  2015-06-24       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.